tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Albano L et al. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. 2013 Transplantation pmid:23982340
Fredericks S et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. 2006 Transplantation pmid:16969296
Marcos A et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. 2004 Transplantation pmid:15480160
Gralla J and Wiseman AC Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. 2009 Transplantation pmid:19502965
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Jain A et al. Pregnancy after liver transplantation under tacrolimus. 1997 Transplantation pmid:9293865
Roth D et al. A prospective study of hepatitis C virus infection in renal allograft recipients. 1996 Transplantation pmid:8623154
Garcia-Criado FJ et al. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. 1997 Transplantation pmid:9293871
Koprak S et al. Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. 1996 Transplantation pmid:8623162
Suzuki H et al. Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. 1997 Transplantation pmid:9293881
Satterthwaite R et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. 1998 Transplantation pmid:9484771
Garrity ER and Mehra MR An update on clinical outcomes in heart and lung transplantation. 2004 Transplantation pmid:15201689
First MR and Fitzsimmons WE New drugs to improve transplant outcomes. 2004 Transplantation pmid:15201693
Lee D et al. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. 2017 Transplantation pmid:27779572
Wozniak LJ et al. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. 2015 Transplantation pmid:26038872
Boldt A et al. The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. 2006 Transplantation pmid:16906043
Kuypers DR et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. 2010 Transplantation pmid:20555228
Sheikh AM et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. 1999 Transplantation pmid:10440408
Gaber AO et al. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. 2013 Transplantation pmid:23423269
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Guethoff S et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. 2013 Transplantation pmid:23423270
Takahara S et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. 1992 Transplantation pmid:1373537
Miyakoshi S et al. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. 2007 Transplantation pmid:17700155
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
Naesens M et al. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. 2007 Transplantation pmid:17700162
Kim YI et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. 1992 Transplantation pmid:1373539
Fujita T et al. Prolonged survival of rat skin allograft by treatment with FK506 ointment. 1997 Transplantation pmid:9326422
Pratschke J et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. 1997 Transplantation pmid:9326428
Jain AB et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. 2004 Transplantation pmid:15077034
Huang E et al. Alemtuzumab induction in deceased donor kidney transplantation. 2007 Transplantation pmid:17984833
Kato T et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. 2007 Transplantation pmid:17984834
Jain A et al. Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. 2014 Transplantation pmid:25285953
Eiras G et al. Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. 1990 Transplantation pmid:1694318
Tze WJ et al. In vitro effects of FK-506 on human and rat islets. 1990 Transplantation pmid:1694319
Tuteja S et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. 2001 Transplantation pmid:11397967
Maes BD et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. 2001 Transplantation pmid:11726827
Kahan BD An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. 1999 Transplantation pmid:10428260
Washburn K et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. 2001 Transplantation pmid:11726831
Reichenspurner H et al. Optimization of the immunosuppressive protocol after lung transplantation. 1999 Transplantation pmid:10428269
Pilmore HL et al. Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. 2001 Transplantation pmid:11726837
Moxey-Mims MM et al. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) 1998 Transplantation pmid:9521193
Jordan ML et al. Long-term results of pancreas transplantation under tacrolius immunosuppression. 1999 Transplantation pmid:10075592
Shapiro R et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. 1999 Transplantation pmid:10075598
Kaplan B et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. 1999 Transplantation pmid:10075604
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Min DI et al. Circadian variation of tacrolimus disposition in liver allograft recipients. 1996 Transplantation pmid:8900327
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. 2011 Transplantation pmid:21107305
Reddy KS et al. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. 2000 Transplantation pmid:10653379
Jain A et al. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. 2000 Transplantation pmid:10653398
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
Borrows R et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. 2006 Transplantation pmid:16421488
Arzouk N et al. Interaction between tacrolimus and fumagillin in two kidney transplant recipients. 2006 Transplantation pmid:16421493
Kadry Z et al. Kaposi's sarcoma in liver transplant recipients on FK506. 1998 Transplantation pmid:9583882
Kandula P et al. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. 2012 Transplantation pmid:23037007
First MR et al. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. 2013 Transplantation pmid:23619735
Woodle ES et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplantation pmid:8830821
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. 1989 Transplantation pmid:2465592
Ninova D et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. 2004 Transplantation pmid:15316360
Ciancio G et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. 2004 Transplantation pmid:15316372
Ho ET et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. 2013 Transplantation pmid:23542469
Berg UB et al. Renal function before and long after liver transplantation in children. 2001 Transplantation pmid:11544422
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Murase N et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. 1993 Transplantation pmid:7682735
Gruessner RW et al. Mycophenolate mofetil in pancreas transplantation. 1998 Transplantation pmid:9721799
Emond JC et al. Improved results of living-related liver transplantation with routine application in a pediatric program. 1993 Transplantation pmid:7682738
Porrini E et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. 2008 Transplantation pmid:18431233
Veroux M et al. Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. 2012 Transplantation pmid:22298033
Naesens M et al. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. 2008 Transplantation pmid:18431234
Dean PG et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. 2008 Transplantation pmid:18431244
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Laskow DA et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8878381
Shoji T et al. Operational tolerance to class I disparate lungs can be induced despite pretransplant immunization with class I allopeptides. 2007 Transplantation pmid:18091523
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. 1996 Transplantation pmid:8878382
Kershner RP and Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996 Transplantation pmid:8878385
McLaren A Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. 2003 Transplantation pmid:14705621
Roberts CA et al. Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. 2002 Transplantation pmid:12364862
Yang H et al. Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. 2002 Transplantation pmid:11907415
Klein IH et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. 2002 Transplantation pmid:11907418
Vincenti F et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. 2002 Transplantation pmid:11907427
Ringe B et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. 2001 Transplantation pmid:11258429
Cantarovich D et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. 2005 Transplantation pmid:15714172
Nguyen L et al. Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. 2012 Transplantation pmid:22960763
Vafadari R et al. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. 2012 Transplantation pmid:22960764
Thomas PG et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. 2007 Transplantation pmid:17565326
Egashira K et al. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. 2003 Transplantation pmid:12698101
Hu H et al. Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. 2003 Transplantation pmid:12698107
Fredericks S and Holt DW TGF-beta quantitation can be tricky. 1999 Transplantation pmid:10480399
Hughes JR et al. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. 1999 Transplantation pmid:10480422
Kuypers DR et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. 2013 Transplantation pmid:23263559
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
White M et al. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. 2006 Transplantation pmid:17006323
Wissing KM et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. 2006 Transplantation pmid:17006324
Gruessner RW et al. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. 2008 Transplantation pmid:18192910